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Cohen et al 225Results: A consensus was reached in 36/38 statements regarding regulatory considerations, extrapolation
of indication, interchangeability, substitution at the pharmacy level, pharmacovigilance, traceability,
naming, biosimilar policy, education, and cost of biosimilars. Example statements include ‘‘Switching a
stable patient from a reference product to a biosimilar product is appropriate if the patient and physician
agree to do so’’ and ‘‘Patients and patients’ organisations should be involved in all decision making and
policy development about the use of biosimilars.’’Conclusion: The International Psoriasis Council Biosimilar Working Group provides consensus statements
for the use of biosimilars in the treatment of patients with psoriasis. We suggest that these statements
provide global guidance to clinicians, healthcare organizations, pharmaceutical companies, regulators,
and patients regarding the development and use of biosimilars in patients with psoriasis. ( JAAD Int
2020;1:224-30.)
Key words: biosimilars; interchangeability; International Psoriasis Council; psoriasis; switching; tumor
necrosis factor inhibitors.CAPSULE SUMMARY
d This study provides consensus
statements from the Biosimilar Working
Group about biosimilar use in patients
with psoriasis, providing global guidance
to clinicians, patients, and other
stakeholders.
d Switching a stable patient from a
reference product to a biosimilar
product is appropriate if the patient and
physician agree to it.INTRODUCTION
Biologic therapies,
including monoclonal anti-
bodies and receptor fusion
proteins targeting tumor ne-
crosis factor-a or interleukins,
have significantly improved
the treatment outcomes for
patients with psoriasis.1-3
Although considerably more
effective than traditional sys-
temic therapies, the high cost
of biologic agents has limited
their use and contributed to
inequalities in the care pro-
vided to patients with psoria-
sis in many countries.1,4,5
One way in which healthcare systems can maxi-
mize the value derived for patients from the money it
spends on biologic medicines6 and widen access to
biologic therapies is through the use of biosimilars.7,8
Biosimilars are drugs that are highly similar, with no
clinically meaningful differences, to originator bio-
logic medicines, as proven by high-level clinical
studies.9 The development and approval of bio-
similars according to the rigorous standards of
pharmaceutical quality, safety, and efficacy are still
associated with significant costs.10 However, in com-
parison to the developmental process for originator
biologics, there is significant emphasis on the phys-
icochemical and functional characterization of bio-
similars, which is considered the foundation for the
regulatory approval of biosimilars, rather than on
clinical testing per se.11,12 Clinical testing for regula-
tory approval must be conducted in a patient
population sensitive enough for the detection of
differences in efficacy or safety between the bio-
similar and reference products.13 Noninferiority orequivalence studies of a
single indication, requiring
sample sizes usually smaller
than those for studies on the
approval of new biologic
agents, are acceptable and
need not be repeated for
every indication of the origi-
nator if extrapolation is
accepted by regulatory
agencies.14 Although this ac-
celerates the developmental
process and reduces the cost
of biosimilar production, the
dermatology community
may find it difficult to inter-pret data collected from biosimilar trials conducted
in dissimilar disease states.15,16 Formerly, most of the
clinical testing of antietumor necrosis factor bio-
similars approved for use in psoriasis had been
performed in patients with rheumatoid arthritis.
The International Psoriasis Council (IPC) called for
clinical studies to be conducted in patients with
psoriasis, and studies have now been conducted in
patients with psoriasis.14,17,18
By definition, biosimilars and originators have
identical primary amino acid sequences. However,
there may be minor differences in glycosylation,
deamination, oxidation, or 3-dimensional structures
between biosimilars and originator biologics, which
may affect their end-target interactions and help
determine differences in efficacy and safety.19,20
Patients and clinicians may be concerned about a
potential loss of efficacy, altered immunogenicity, or
unanticipated differences in adverse effects when
switching to a biosimilar.21,22
Dermatologists worldwide are faced with the
need to choose between an originator or a biosimilar
Abbreviations used:
BSWG: Biosimilar Working Group
IPC: International Psoriasis Council
NGT: nominal group technique
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originator to a biosimilar in patients established on
treatment.23 However, with significant financial in-
centives driving the prescription of biosimilars in
many health economies, biologic treatment deci-
sions may become more physician-independent in
the future.24 Multiple biosimilar medications now
exist, which may result in numerous changes in
therapy for individual patients, making it almost
impossible to attribute safety signals to a specific
biosimilar medication.14 Interchangeability is a major
challenge for dermatologists, and traceability is
imperative in order to collect accurate pharmacovi-
gilance data on adverse events in patients with
psoriasis who have been managed with biosimilar
and originator biologic treatments.24
The IPC, a network of more than 100 experts on
psoriasis dedicated to improving psoriasis care
around the globe, has previously urged dermatolo-
gists to actively participate in developing policies
for biosimilar prescription worldwide and has
published reports on many aspects of biosimilar
prescription.11,14,16,23,24 As clinicians continue to
wrestle with the opportunities and challenges that
biosimilar therapeutics offer, the IPC has identified
the need for clear guidance on the use of biosimilars
in the treatment of psoriasis. In the current report, we
describe a semiqualitative structured process em-
ployed by the IPC and the consensus statements on
biosimilar prescription that have been agreed upon
by IPC councilors.
MATERIALS AND METHODS
The study was conducted within the framework
of the IPC Biosimilar Working Group (BSWG), which
includes IPC councilors who are interested in bio-
similars. The group conducted 1-2meetings per year,
in which the various aspects of biosimilars were
discussed. Themeeting attendees includedmembers
of the IPC BSWG, as well as external experts and
pharma representatives. Pharma representatives
participated in the meeting to present data from their
respective companies. Discussions were held with
the participation of the BSWG members, guests, and
pharma representatives. When sensitive matters
were discussed (eg, prioritization of drug use in
psoriasis), the guest scholars and pharma represen-
tatives were asked to leave themeeting room and notparticipate in the debate. Thus, the IPC BSWG
members were at liberty to express their opinions.
The consensus statements were reached using the
nominal group technique (NGT).25 NGT is a process
used for solution generation, decision-making, and
consensus agreement considering each participant’s
opinion. The NGT exercise used in this study had 3
stages: 1) Identification of essential issues on the
use of biosimilars in patients with psoriasis, 2)
Discussion and collapsing of the statements, and 3)
Prioritizing and ranking of the statements by voting.
In the identification stage, the participants were
requested to submit statements about the use of
biosimilars via e-mail correspondence. These state-
ments were collected by a group facilitator, who led a
consensus-reaching meeting of the IPC councilors
of the BSWG. The meeting took place in February
2019. During the meeting, it was possible to submit
additional statements. In the second stage of the NGT
exercise, the participants discussed each idea on the
list so that the meaning of the statements was made
clear to everyone. Thereafter, the statements were
collapsed to 38 major statements.
Twenty-three councilors of BSWG participated in
the consensus voting of the statements on bio-
similars, which were grouped into 10 different
categories (in alphabetical order): biosimilar policy,
cost of biosimilars, education, extrapolation of indi-
cation, interchangeability, naming, pharmacovigi-
lance, regulatory considerations, substitution at the
pharmacy level, and traceability. In the voting stage,
the participants were asked to express their agree-
ment on each statement using an online survey
conducted using SurveyMonkey (https://www.
surveymonkey.co.uk/). The degree of agreement
with each statement was ranked into 5 categories:
‘‘not at all,’’ ‘‘slightly,’’ ‘‘moderately,’’ ‘‘very much,’’
and ‘‘extremely,’’ with the latter 3 implying a positive
opinion. Approval of the consensus statements was
predefined as[80% positive opinions in the survey.
The study was approved for publication by the
IPC. All 38 consensus statements were reviewed and
voted upon by 100% of the participants in the survey.
RESULTS
The consensus approval was reached for 36 out
of the 38 statements (94.7%), with 100% positive
opinions (‘‘moderately,’’ ‘‘very much,’’ and
‘‘extremely’’) in 21 (55.3%) (Table I). In approxi-
mately one-third (33.8%) of the statements, the
‘‘slightly’’ agreement choice was recorded. The ‘‘not
at all’’ response was recorded in less than 1 quarter of
the statements (23.7%). The categories with 100%
positive opinions included cost, pharmacovigilance,
and traceability. The categories with[90% positive




1 Evaluation of biosimilar products must meet the rigorous standards of regulatory guidance
(EMA, FDA, WHO).
23 100%
2 Biosimilar assessments, including physiochemical, pharmacokinetic, and functional analytical
assays, must meet rigorous standards.
23 100%
3 In comparison to the reference product, a biosimilar product should demonstrate no clinically
meaningful differences in efficacy, safety, or immunogenicity.
23 100%
4 Biosimilar trials are intended to demonstrate clinical equivalence to the reference product. Use
of the same endpoints (efficacy and safety) of the pivotal trials of the reference product is
preferable.
23 100%
5 Biosimilar clinical trials should include both elements of crossover and parallel design. 23 100%
6 Biosimilar clinical trial designs incorporating at least 2 switches between the reference product
and biosimilar are preferable.
22 96%
7 Studies designed to examine switching between multiple biosimilars can provide relevant
information.
22 96%
8 Trials of biosimilars for the indication of psoriasis should be performed in patients with
psoriasis.
21 91%
9 Extrapolation of indications from trials in other diseases, as determined by the regulatory
agencies, is acceptable.
19 83%
10 Published clinical trial data demonstrated that a single switch from an innovator to a biosimilar
is safe and effective.
22 96%
11 Prescribing biosimilars to biologic-na€ıve patients with psoriasis is appropriate if the patient and
physician agree to do so.
22 96%
12 Switching a stable patient from a reference product to a biosimilar product is appropriate if the
patient and physician agree to do so.
20 87%
13 Multiple switches between various biosimilars and reference biologics is not the preferred
option but is acceptable.
15 65%
14 Treatment switches should not occur in less than an adequate period of time (usually 6 months)
from initiation of the reference product, allowing full assessment of its therapeutic effect.
23 100%
15 Switching between different biosimilars should be performed with caution, until more evidence
is generated supporting this practice.
17 74%
16 Clinicians should be notified and should provide approval prior to any originator or biosimilar
drug substitution being made.
22 96%
17 Clinicians should be given explicit authority to override any suggested substitutions. 21 91%
18 Registries, consortia, and large, prospective databases of patients treated with biosimilars
should be established.
23 100%
19 Health claims data should be used to provide pharmacovigilance when using biosimilars and
reference products.
23 100%
20 Traceability should be ensured so that a specific biosimilar, and/or reference product, its
producer, and its manufacturing history (eg, lot number) can be reliably identified.
23 100%
21 Each biosimilar name should be easily distinguishable from its biologic reference product and
other biosimilars.
22 96%
22 Using a biosimilar brand name may be a suitable option. 20 87%
23 One biosimilar name is preferable to use in every country. 22 96%
24 Patients and patients’ organizations should be involved in all decision-making and policy
development about the use of biosimilars.
22 96%
25 Dermatologists and professional organizations should take an active role in the development of
biosimilar prescribing policies in their respective healthcare and governmental agencies.
23 100%
26 Biosimilars should not prevent or delay access to the use of new biologic drugs. 23 100%
27 Dermatology leadership should develop guidelines for the use of biosimilars. 23 100%
28 Biosimilar resources for physicians should include summarized information on the quality of the
comparability data used to demonstrate biosimilarity for approval (PK and PD profiles, clinical
trial data).
23 100%
29 The impact of biosimilar education on prescribers should be measured with an emphasis on
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30 Practice guidelines for biosimilars should be developed at a local level, which will differ across
countries throughout the world.
20 87%
31 Translation of biosimilar information from physicians to patients is needed for clear
understanding.
23 100%
32 Dermatology leadership should develop educational programs for dermatologists about the
complexity of manufacturing and use of biosimilars.
22 96%
33 Biosimilar companies are advised to communicate the quality of manufacturing to
dermatologists.
23 100%
34 Cost of biosimilars should be low enough to genuinely improve patients’ access to these drugs. 23 100%
35 Biosimilars are therapeutic options over their originator products if their use provides cost
savings to patients and/or reduces financial burden to healthcare system.
23 100%
36 Biocopies, ’’intended copies‘‘, and/or ’’biomimic products‘‘, which are not biosimilars, should
not be used.
23 100%
37 Education is needed to distinguish biosimilars from biomimics. 23 100%
38 Biomimics should not have the same name as biosimilars or originator products. 23 100%
EMA, European Medicines Agency; PD, pharmacodynamics; PK, pharmacokinetics.
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lance regulatory considerations, substitution at phar-
macy level, and traceability.
A consensus was reached, and all the statements
were agreed upon ([80% positive opinions) in the
following categories: biosimilar policy, cost of bio-
similars, education, extrapolation of indication,
naming, pharmacovigilance, regulatory consider-
ations, substitution at pharmacy level, and trace-
ability. A consensus was not reached for only 2
statements, both of them in the interchangeability
category. The statement ‘‘Multiple switches between
various biosimilars and reference biologics is not
the preferred option but is acceptable’’ received
only 65.7% positive opinions and was, therefore,
not agreed upon. A consensus on the statement
‘‘Switching between different biosimilars should be
performed with caution, until more evidence is
generated supporting this practice’’ was not reached
either, with only 73.9% positive opinions (28/38
voters). These results indicate that single or multiple
switching between biosimilars in patients with pso-
riasis is still open to argument in the councilors’
opinions.
DISCUSSION
Biologic therapies have led to significant improve-
ments in the outcomes of patients with psoriasis,
with the downside of increased healthcare costs.26
The signature promise of cost-effective biosimilars is
to improve patient access to highly effective treat-
ments earlier in the therapy cycle, decrease costs,
and maintain improved health outcomes.27 This
presents an opportunity for dermatologists to deliver
high-quality and high-value care.14,26,28The patents of several key biologic therapies for
the treatment of psoriasis have either already expired
or will expire by 2020.28 This is driving interest in
biosimilar drug development by pharmaceutical
manufacturers.28 However, biosimilar use and their
subsequent market uptake are contingent on physi-
cians’ confidence and willingness to prescribe bio-
similars in clinical practice.28 In this paper, the IPC
provides a suite of consensus statements on the use
of biosimilars for the management of psoriasis across
10 different categories: biosimilar policy, cost of
biosimilars, education, extrapolation of indication,
interchangeability, naming, pharmacovigilance, reg-
ulatory considerations, substitution of pharmacy
level, and traceability. However, some IPC members
expressed concerns regarding switching of therapies
between different biosimilars and did not reach a
consensus regarding multiple switches between
originator biologics and biosimilars.
The US Food and Drug Administration’s (FDA)
designation of interchangeability means that a bio-
similar is expected to produce the same clinical
results as the reference product when substituted at
any point in therapy and to present no greater safety
risk than continuous treatment using the reference
product; therefore, an interchangeable product may
be substituted without the intervention of the pre-
scribing provider.26 Draft guidance for full inter-
changeability, including automatic substitution, of a
biologic medicine, as developed by the FDA, pro-
posed that drug manufacturers perform at least 1
randomized clinical trial comparing patients who
undergo multiple treatment switches (at least 3)
with those continued on the same treatment.29 In
the past, many randomized trials have involved only
JAAD INT
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EGALITY trial with a biosimilar of etanercept,
GP2015, randomized patients with moderate-to-
severe chronic plaque psoriasis to continue on the
same treatment with the originator or were made to
undergo a sequence of 3 switches between the
originator and the biosimilar at 6-week intervals.31
The study assessed the effect of the treatment
switches on efficacy, safety, and immunogenicity
and showed that the triple switching had no effect
on the safety or efficacy of the therapy.31,32 During
the study, 6 patients exhibited transient presence of
low titers of non-neutralizing anti-drug antibodies (5
patients during the first 4 weeks of treatment and 1
patient at week 36).31 During the second (triple
switching) phase of the treatment, none of the patient
participants exhibited the presence of anti-drug
antibodies, confirming the low immunogenic poten-
tial of both the biosimilar and originator etanercept.31
Furthermore, a 51-week, double-blinded, phase
III study demonstrated the biosimilarity between
GP2017 and the reference biologic adalimumab,
with equivalent efficacy and similar safety and
immunogenicity levels, in adult patients with
active, clinically stable, moderate-to-severe plaque
psoriasis.33 Further investigation demonstrated that
switching between GP2017 and the reference prod-
uct up to 4 times had no detectable impact on the
efficacy, safety, or immunogenicity.33
On the other hand, a Dutch multicenter prospec-
tive open-label study of patients with inflammatory
arthropathies, including psoriatic arthritis, anky-
losing spondylitis, and rheumatoid arthritis (the
BIO-SWITCH study), investigated switching from
the originator infliximab to the biosimilar CT-P13.31
Overall, 24% of 197 patients discontinued the treat-
ment with the biosimilar because of a perceived lack
of effect, adverse events, or a combination of both.34
Further analysis disclosed that 78% of the reported
adverse events could be classified as subjective
health complaints.34 This might be attributed to the
nocebo effect associated with the patients’ negative
expectations concerning the therapy, which may
have led to the subjective health complaints (ie,
symptoms perceptible only by the patient) and
discontinuation of the therapy.35 The nocebo effect,
which can also be defined as the opposite of placebo
effect, may explain why the rate of discontinuation of
the therapy can be higher in open-label studies than
in randomized controlled trials.30 These data suggest
that acceptance and persistence rates after switching
to a biosimilar product may be influenced by the way
in which switching is communicated to the patient.34
Our study did have some limitations. First, we
only surveyed expert opinions. However, our surveyreflects the debate that we, as experts, have been
considering in recent years, including the general,
specific, and controversial aspects of biosimilar pre-
scription for psoriasis. Second, for the statements for
which a consensus was not reached, we did not
elucidate the areas of disagreement as this was
beyond the scope of this study. Finally, our paper
does not provide a comprehensive review of the
literature and evidence regarding biosimilars as this
has been provided by our previous papers on
biosimilars.11,14,23,24
In this paper, the IPC BSWG provides consensus
statements for the use of biosimilars in the treat-
ment of patients with psoriasis. These consensus
statements are intended to offer guidance to clini-
cians, healthcare organizations, pharmaceutical in-
dustry, regulators, and patients regarding the
development and use of biosimilars for the treat-
ment of psoriasis around the world. In conclusion,
the IPC endorses evidence from clinical trials and
increasing experience from daily clinical practice,
which show that biosimilars are equivalent to
reference products in terms of quality, efficacy,
and safety profiles, including the extrapolation of
the indications. However, switching clinically stable
patients from originator biologics to their biosimilar
alternatives still raises some concerns, although
according to the available clinical trials and litera-
ture reviews, a single switch from an originator to a
biosimilar is not associated with any significant risk
or loss of efficacy.36 Nevertheless, clinical evidence
regarding the safety of multiple switches is limited,
and the IPC strongly endorses continued patient
monitoring using a registry and long-term observa-
tional studies to provide more data. The IPC also
recognizes the need for careful monitoring of
patient after a treatment switch and detailed
recording of the therapy prescribed in the medical
records.
The manuscript was developed through the work of
the IPC BSWG. The IPC BSWG members who hold a
postion in the paper are: Robert Strohal, Denis Jullien,
Wolf-Henning Boehncke, Nancy Podoswa, Marc Bourcier,
Claus Zachariae, Cesar Gonzalez, Omid Zargari, Menno de
Rie, Yves Poulin, Andre Vicente Esteves de Carvalho,
Caitriona Ryan, Colby Evans, Peter Foley, Fernando
Valenzuela, Murlidhar Rajagopalan, Lone Skov, and Peter
van de Kerkhof.
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